Overview

Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Africa, Asia, Europe, Japan, and North and South America. The aim of this trial is to evaluate the safety and efficacy of activated recombinant human factor VII analogue (vatreptocog alfa (activated)) in haemophilia patients with inhibitors.
Phase:
Phase 2
Details
Lead Sponsor:
Novo Nordisk A/S